http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2767567-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_918b5baf120462b6f6ea606007c4ce5c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-121 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0482 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K103-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F5-00 |
| filingDate | 2020-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_472e583346b565ad9cd5043a6463957c |
| publicationDate | 2022-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2767567-C1 |
| titleOfInvention | COMPLEX COMPOUNDS CONTAINING RADIONUCLIDE 227Th, AS WELL AS BISPHOSPHONATE FRAGMENT, METHODS FOR THEIR PRODUCTION, AS WELL AS POTENTIAL USE AS ACTIVE SUBSTANCE IN COMPOSITION OF OSTEOTROPIC RADIOPHARMACEUTICAL DRUG |
| abstract | FIELD: nuclear medicine.SUBSTANCE: invention relates to nuclear medicine, namely to the development of a potential osteotropic therapeutic radiopharmaceutical drug, active substance of which is a complex compound of the structure Y:227Th-Chel-Zoledron, where Zoledron is a fragment corresponding to the structure:Chel is a fragment corresponding to bifunctional chelating agents: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (-DOTA); 2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1-yl)pentanedioic acid (-DOTAGA); 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (-TETA); 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetrapropionic acid (-TETPA); 1,4,7,10,13,16-hexaazacycloctadecane-1,4,7,10,13,16-hexaacetic acid (-HEHA); 1,4,7,10,13-pentaazacyclopentadecane-1,4,7,10,13-pentacetic acid (-PEPA); diethylenetriamine pentacetic acid (-DTPA); trans-cyclohexyl-diethylenetriamine pentaacetic acid (-CHX-DTPA); S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (p-SCN-Bn-DOTA); [(R)-2-amino-3-(4-isothiocyanatophenyl)propyl]-diamine-pentacetic acid (p-SCN-Bn-DTPA); [(R)-2-amino-3-(4-isothiocyanatophenyl)propyl]-trans-(S,S)-cyclohexane-1,2-diamine-pentacetic acid (p-SCN-Bn-CHX-A-DTPA); S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamide (p-SCN-Bn-TCMC); S-2-(4-isothiocyanatobenzyl)-1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (p-SCN-Bn-TETA); S-2-(4-isothiocyanatobenzyl)-1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetrapropionic acid (p-SCN-Bn-TETPA); S-2-(4-isothiocyanatobenzyl)-1,4,7,10,13,16-hexaazacycloctadecane-1,4,7,10,13,16-hexacetic acid (p-SCN-Bn-HEHA); S-2-(4-isothiocyanatobenzyl)-1,4,7,10,13-pentaazacyclopentadecane-1,4,7,10,13-pentacetic acid (p-SCN-Bn-PEPA), and in which radionuclide227Th is part of the compound Y due to the formation of stable coordination bonds with the Chel fragment.EFFECT: proposed complex compound of the structure Y as part of a potential osteotropic radiopharmaceutical drug, in addition to its therapeutic properties, such as reducing bone resorption due to the bisphosphonate fragment, and cytotoxic effect due to the formation of α-particles in the immediate vicinity of the pathological focus due to α-decay of radionuclide227Th, is a potential in vivo generator of radionuclide223Ra.7 cl, 5 tbl |
| priorityDate | 2020-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 77.